Patricia Lawman

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Escherichia Coli

Peripheral Blood

Toll Like Receptor

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular cancer therapeutics 23 (8) (2024)
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular cancer therapeutics 23 (8) (2024)
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-human stage III/IV melanoma clinical trial of immune priming agent IFx-Hu2.0. Molecular cancer therapeutics (2024)
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, Amod A Sarnaik, Zeynep Eroglu, Nikhil I Khushalani, Christopher W Dukes, Alejandra Chamizo, Marina Bastawrous, Edward T Garcia, Ashraf Dehlawi, Pei-Ling Chen, Deanryan B De Aquino, Vernon K Sondak, Ahmad A Tarhini, Youngchul Kim, Patricia Lawman, Shari A Pilon-Thomas
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular cancer therapeutics 23 (8) (2024)